Immunization of patients with autoimmune inflammatory rheumatic diseases (the EULAR recommendations)

Lupus

Volumn 21, Issue 2, 2012, Pages 162-167

  Van Assen, S ^a   Bijl, M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

autoimmune inflammatory rheumatic diseases; infection; vaccination

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; AUTOIMMUNE DISEASE; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; IMMUNIZATION; INFECTION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

AUTOIMMUNE DISEASES; EUROPE; GUIDELINES AS TOPIC; HUMANS; IMMUNIZATION; INFLUENZA, HUMAN; RHEUMATIC DISEASES; VACCINES;

EID: 84855790174     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311429555     Document Type: Article

References (44)

1. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 ; 70: 414-422
2. Plotkin SA, Orenstein WA, Offit PA Vaccines. 2008. Philadelphia: Saunders Elsevier ; 2008 :
3. Treanor JJ. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Influenza virus. 7th ed. Elsevier, 2008.
4. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010 ; 362: 1708-1719
5. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007 ; 28: 222-242 (Pubitemid 46676916)
6. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002 ; 35: 370-377 (Pubitemid 34852565)
7. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 1998 ; 158: 1769-1776 (Pubitemid 28421420)
8. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003 ; 115: 63-73
9. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000 ; 18: 3040-3049 (Pubitemid 30303809)
10. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 1994 ; 8: 469-476 (Pubitemid 24102296)
11. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 ; 289: 179-186 (Pubitemid 36068705)
12. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009 ; 9: 493-504
13. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006 ; 176: 6333-6339
14. Gravenstein S, Drinka P, Duthie EH, et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc. 1994 ; 42: 245-251 (Pubitemid 24079864)
15. McElhaney JE, Ewen C, Zhou X, et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine. 2009 ; 27: 2418-2425
16. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis. 2006 ; 12: 48-54 (Pubitemid 43143535)
17. Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008 ; 15: 1042-1053 (Pubitemid 352018317)
18. Holvast A, van Assen S, de Haan A, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford). 2009 ; 48: 1294-1299
19. Holvast A, van Assen S, de Haan A, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum. 2009 ; 60: 2438-2447
20. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011 ; 29: 1643-1648
21. Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2007 ; 66: 1402-1403 (Pubitemid 47492493)
22. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008 ; 67: 937-941 (Pubitemid 351956654)
23. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2009 ; 62: 75-81
24. Saad CG, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis. 2011 ; 70: 1068-1073
25. Bridges MJ, Coady D, Kelly CA, Hamilton J, Heycock C. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2003 ; 62: 685-685
26. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2007 ; 66: 837-838 (Pubitemid 46846712)
27. Doe S, Pathare S, Kelly CA, Heycock CR, Binding J, Hamilton J. Uptake of influenza vaccination in patients on immunosuppressant agents for rheumatological diseases: a follow-up audit of the influence of secondary care. Rheumatology (Oxford). 2007 ; 46: 715-716 (Pubitemid 46523323)
28. Feuchtenberger M, Kleinert S, Schwab S, et al. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int. 2011 ;:
29. Meynaar IA, 't Wout JW, Vandenbroucke JP, van Furth R. [Implementation of influenza vaccination in 3 hospitals]. Ned Tijdschr Geneeskd. 1992 ; 136: 180-183
30. Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science. 2004 ; 304: 1808-1810 (Pubitemid 38787898)
31. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther. 2010 ; 10: 639-651
32. Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine. 2009 ; 27: 3345-3348
33. Ori E, Sharon A, Ella M, et al. The efficacy and safety of vaccination against pandemic 2009 influenza a (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken). 2011 ; 63: 1062-1067
34. McElhaney JE. Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging Health. 2008 ; 4: 603-613
35. Saurwein-Teissl M, Zisterer K, Schmitt TL, Gluck R, Cryz S, Grubeck-Loebenstein B. Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Clin Exp Immunol. 1998 ; 114: 271-276 (Pubitemid 28505729)
36. Bungener L, Huckriede A, de Mare A, Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine. 2005 ; 23: 1232-1241 (Pubitemid 40126526)
37. Herzog C, Hartmann K, Kunzi V, et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine. 2009 ; 27: 4381-4387
38. Huckriede A, Bungener L, Ter Veer W, et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine. 2003 ; 21: 925-931 (Pubitemid 36131101)
39. Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine. 2005 ; 23 (Suppl 1). S26 - S38
40. Song JM, Van Rooijen N, Bozja J, Compans RW, Kang SM. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A. 2011 ; 108: 757-761
41. Geeraedts F, Goutagny N, Hornung V, et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 2008 ; 4: e1000138 - e1000138
42. Taylor DN, Treanor JJ, Strout C, et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine. 2011 ; 29: 4897-4902
43. Gelinck LB, van den Bemt BJ, Marijt WA, et al. Intradermal influenza vaccination in immunocompromised patients is immunogenic and feasible. Vaccine. 2009 ; 27: 2469-2474
44. Shoenfeld Y, Agmon-Levin N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011 ; 36: 4-8